Video

Igor Koralnik from Rush University Medical Center: Progressive Multifocal Leukoencephalopathy a Continuing Problem Across Many Conditions

Author(s):

Progressive multifocal leukoencephalopathy, also known as PML is a problem which can affect a select number of patients with multiple sclerosis as well as other conditions which involve the immune system. What can be done to address the condition is still being determined by the medical community.

Progressive multifocal leukoencephalopathy, also known as PML is a problem which can affect a select number of patients with multiple sclerosis as well as other conditions which involve the immune system. What can be done to address the condition is still being determined by the medical community.

Igor N. Koralnik, MD, from Rush University Medical Center discussed what is known about the condition and what still needs to be learned during the annual ECTRIMS conference held in London. The virus, which can kill brain cells can be very difficult to treat as it is a progressive condition rather than a relapsing issue like that seen in multiple sclerosis. As a result, Koralnik said making the right diagnosis and addressing treatment quickly is very important. The treatment is further complicated because it can be triggered by some multiple sclerosis drugs including natalizumab.

Related Videos
Christian Sadaka, MD: Significant Increase in Pediatric Gastroparesis Hospital Admissions After COVID-19
Developing Risk Assessment Tools for Viruses in School
Getting Black Men Involved in Their Health Care, Clinical Research
Patient Involvement in Advanced HF Treatment, with Ashley Malliett, DMSc, MPAS, PA-C
Aaron Henry, PA-C, MSHS: Regaining Black Male Patient Trust in the Doctor's Office
How to Adequately Screen for and Treat Cognitive Decline in Primary Care
James R. Kilgore, DMSc, PhD, PA-C: Cognitive Decline Diagnostics
What Should the American Academy of Physician Associates Focus on in 2025?
Danielle O'Laughlin, PA-C, MS: Navigating Long-Term Risks, Family Planning in PCOS
© 2024 MJH Life Sciences

All rights reserved.